SPY314.60+0.82 0.26%
DIA259.53+0.49 0.19%
IXIC10,425.10+81.22 0.79%

Relmada Therapeutics Announces Notice Of Allowance For Patent In Canada Covering REL-1017 For Treatment Of Psychiatric Symptoms

Patent Further Expands Company's Intellectual Property Protection for REL-1017 a Novel NMDA Receptor Antagonist, in a Major Global Market NEW YORK, June 23, 2020 /PRNewswire/ --Relmada Therapeutics, Inc.

Benzinga · -

Patent Further Expands Company's Intellectual Property Protection for REL-1017 a Novel NMDA Receptor Antagonist, in a Major Global Market

NEW YORK, June 23, 2020 /PRNewswire/ --Relmada Therapeutics, Inc. (NASDAQ:RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the receipt of a Notice of Allowance from the Canadian Intellectual Property Office for Relmada's patent application number, 2,893,238, titled, "d-Methadone for the Treatment of Psychiatric Symptoms." The patent that will issue from this allowed application provides broad coverage in Canada for REL-1017 (d-methadone, dextromethadone,), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of symptoms associated with a wide range of psychological and psychiatric disorders, including depression, anxiety, fatigue, and mood instability.